The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
A team of researchers at UTMB developed a drug that attacks the bad stuff in the brain that causes Alzheimer's. Now, there's ...
The Food and Drug Administration approved a new Eli Lilly drug this month that treats Alzheimer's disease. Kisunla is an IV ...
Beckman Coulter will use the antibody as part of a p-tau 217 in vitro diagnostic on its DxI 9000 Immunoassay Analyzer to aid in the diagnosis of the disease.
The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...
Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...
The latest drug is showing promising results for adults with early Alzheimer's symptoms, mild cognitive impairment (MCI), and ...